301393.SZ
昊帆生物
SZSE · C 制造业 · CN
CNY 61.32
−6.28%Aug 24, 2026, 07:56 UTC
Haofan Biotech announced its first-half 2026 results: revenue of 379 million yuan, up 40.30% year-on-year; net profit attributable to shareholders of 70.7463 million yuan, down 6.77% year-on-year.
Source:Jul 30, 2026, 08:39 UTC
Hangzhou First, a controlled subsidiary of Haofan Biotech, was prosecuted by the procuratorate for environmental pollution crimes.
Source:Jul 7, 2026, 08:26 UTC
Haofan Biotech announced that 1,863,000 pre-IPO shares will be unlocked and become tradable on July 13, 2026.
Source: